Kevin Kalinsky, MD, MS, provides guidance on treating a patient with HR-positive breast cancer with a CDK4/6 inhibitor, and recommends management strategies for patients who develop relapsed disease.
EP. 1: Case Impressions: A 67-Year-Old With HR+ Breast Cancer
Kevin Kalinsky, MD, MS, presents a case of ER-positive/PR-positive breast cancer and highlights the prevalence of cases such as this in the United States.
EP. 2: HR+ Breast Cancer: Prognostic Indicators
Criteria used by breast oncologists to risk stratify patients who present with HR-positive breast cancer.
EP. 3: CDK4/6 Inhibition in Early-Stage HR+, HER2- Breast Cancer
The rationale for treating patients with early-stage HR-positive breast cancer with abemaciclib and endocrine therapy.
EP. 4: CDK4/6 Inhibitors for Advanced HR+ Breast Cancer
An overview of CDK4/6 inhibitors available for patients with advanced or metastatic HR-positive breast cancer, and recommendations for managing common adverse events associated with therapy.
EP. 5: HR+ Breast Cancer: Future Treatment Opportunities
Guidance on how to treat a 67-year-old patient with ER-positive/PR-positive breast cancer, and additional therapies in the pipeline that have the potential to improve treatment.
2 Clarke Drive Cranbury, NJ 08512